JP2002513768A5 - - Google Patents

Download PDF

Info

Publication number
JP2002513768A5
JP2002513768A5 JP2000546792A JP2000546792A JP2002513768A5 JP 2002513768 A5 JP2002513768 A5 JP 2002513768A5 JP 2000546792 A JP2000546792 A JP 2000546792A JP 2000546792 A JP2000546792 A JP 2000546792A JP 2002513768 A5 JP2002513768 A5 JP 2002513768A5
Authority
JP
Japan
Prior art keywords
gdf
pharmaceutical preparations
inhibitor
individuals
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000546792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002513768A (ja
JP4544742B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/010089 external-priority patent/WO1999056768A1/en
Publication of JP2002513768A publication Critical patent/JP2002513768A/ja
Publication of JP2002513768A5 publication Critical patent/JP2002513768A5/ja
Application granted granted Critical
Publication of JP4544742B2 publication Critical patent/JP4544742B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000546792A 1998-05-06 1999-05-06 Gdf−8の阻害による糖尿病の処置法 Expired - Lifetime JP4544742B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8449098P 1998-05-06 1998-05-06
US60/084,490 1998-05-06
PCT/US1999/010089 WO1999056768A1 (en) 1998-05-06 1999-05-06 Methods for treating diabetes by inhibiting gdf-8

Publications (3)

Publication Number Publication Date
JP2002513768A JP2002513768A (ja) 2002-05-14
JP2002513768A5 true JP2002513768A5 (cg-RX-API-DMAC7.html) 2006-07-06
JP4544742B2 JP4544742B2 (ja) 2010-09-15

Family

ID=22185291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000546792A Expired - Lifetime JP4544742B2 (ja) 1998-05-06 1999-05-06 Gdf−8の阻害による糖尿病の処置法

Country Status (8)

Country Link
US (6) US6368597B1 (cg-RX-API-DMAC7.html)
EP (1) EP1075272B1 (cg-RX-API-DMAC7.html)
JP (1) JP4544742B2 (cg-RX-API-DMAC7.html)
AU (1) AU765214B2 (cg-RX-API-DMAC7.html)
CA (1) CA2331410C (cg-RX-API-DMAC7.html)
DE (1) DE69941116D1 (cg-RX-API-DMAC7.html)
ES (1) ES2330062T3 (cg-RX-API-DMAC7.html)
WO (1) WO1999056768A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
ES2330062T3 (es) * 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7510851B2 (en) * 2001-12-17 2009-03-31 Metabolex, Inc. Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
AU2003267246A1 (en) * 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2003297460A1 (en) * 2002-12-19 2004-07-14 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005066204A2 (en) * 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
CA2558478A1 (en) * 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
US20070178095A1 (en) * 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
MX2007000976A (es) * 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
MX2007008132A (es) * 2004-12-30 2007-07-20 Schering Plough Ltd Vacuna para aumentar el crecimiento basada en epitopes neutralizantes.
EP1864139A2 (en) * 2005-03-23 2007-12-12 Wyeth Detection of an immune response to gdf-8 modulating agents
CA2538208A1 (en) * 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
US7888486B2 (en) 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
KR101135220B1 (ko) * 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20070149458A1 (en) * 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
HRP20130320T1 (en) * 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
KR20120023787A (ko) 2009-05-22 2012-03-13 가부시키가이샤 에리나 대사증후군의 예방제 및/또는 치료제
WO2011087946A1 (en) 2010-01-15 2011-07-21 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
PH12013500315A1 (en) 2010-08-16 2013-04-29 Amgen Inc Antibodies that bind myostatin, compositions and methods
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
MY177331A (en) * 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
CN104931327B (zh) * 2015-03-24 2018-10-19 重庆医科大学 微米级生物材料石蜡切片方法
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
IL276921B2 (en) 2018-03-01 2025-12-01 Regeneron Pharma Methods for altering body composition
WO2020075845A1 (ja) * 2018-10-12 2020-04-16 シーシーアイホールディングス株式会社 クラスiのグルコーストランスポーター(glut)の発現誘導剤、並びにこれを用いた医薬組成物および飲食品組成物
CN110408616B (zh) * 2019-07-09 2021-06-15 中南民族大学 GLUT4基因敲除的sgRNA、A549细胞系及其构建方法
KR20220054608A (ko) 2019-09-03 2022-05-03 노파르티스 아게 ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
CA2157577C (en) * 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
WO1999006559A1 (en) * 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
ES2330062T3 (es) * 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
EE200200025A (et) * 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto

Similar Documents

Publication Publication Date Title
JP2004503598A5 (cg-RX-API-DMAC7.html)
JP2002527727A5 (cg-RX-API-DMAC7.html)
IL170685A0 (en) Protein conjugate
WO2002015920A3 (en) Treatment of hyperproliferative diseases
MX353044B (es) Liberacion sostenida de anti-infecciosos.
ES2178228T3 (es) Cepas fungicas para la expresion de proteinas.
Kay et al. Enhancement of human lymphocyte natural killing function by non-opioid fragments of β-endorphin
CA2330183A1 (en) Novel insulin analogs with enhanced zinc binding
RU2004114865A (ru) Композиция и способ лечения диабета
WO2000066173A3 (en) Targeting of infectious agents bearing host cell proteins
Morimoto et al. Photosensitivity from pyridoxine hydrochloride (vitamin B6)
RU2005118425A (ru) Цитомодуляторные пептиды для лечения интерстициального цистита
Kleinbloesem et al. Pharmacokinetics and bioavailability of percutaneous ibuprofen.
JP2004520009A5 (cg-RX-API-DMAC7.html)
JP2002201141A5 (cg-RX-API-DMAC7.html)
WO2001054707A3 (de) Veränderung von oberflächenproteomem durch aminopeptidase-inhibitoren
Witte et al. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S, 3S, 5S)-2-azabicyclo [3.3. 0] octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
CA2322055A1 (fr) Nouvelle famille de canaux potassium de mammiferes mecanosensibles et actives par les acides gras polyinsatures et leur utilisation notamment pour le criblage de drogues
WO2001075095A1 (fr) Procede de production de proteine de recombinaison
BR0009636B1 (pt) processo para a preparação de insulina madura ou um derivado de insulina madura.
Smith et al. Once-daily monotherapy with trandolapril in the treatment of hypertension.
JP2004505635A5 (cg-RX-API-DMAC7.html)
CA2241941A1 (en) Therapeutic agent containing .omega.-feline interferon for treating feline aids virus infections and feline atopic dermatitis
Green et al. The disposition of four tetracyclines in normal subjects
Enyeart et al. Reciprocal modulation of voltage-gated and background K+ channels mediated by nucleotides and corticotropin